SCHEMBL6009965

SCHEMBL6009965

C[C@](F)(CS(=O)(=O)O)NCC1CCCCC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 3/20 0.35
MLYCD O95822 1/20 0.35
EPHX1 P07099 2/20 0.35
ADH1B P00325 1/20 0.34
ADH1C P00326 1/20 0.34
ADH1A P07327 1/20 0.34
ADH4 P08319 1/20 0.34
ADH7 P40394 1/20 0.34
HDAC4 P56524 2/20 0.33
CA2 P00918 2/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP3 P08254 1/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33
CA9 Q16790 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6009995 1.00 HDAC6 (0.35) HDAC6MLYCDEPHX1ADH1BADH1C
SCHEMBL6009868 0.98 HDAC6 (0.33) HDAC6MLYCDEPHX1ADH1BADH1C
SCHEMBL6009419 0.98 HDAC6 (0.33) HDAC6MLYCDEPHX1ADH1BADH1C
SCHEMBL6009077 0.92 CNR2 (0.32) CNR2PDK1PDK2PDK3PDK4
SCHEMBL5501993 0.92 CNR2 (0.32) CNR2PDK1PDK2PDK3PDK4
SCHEMBL6009986 0.77 PDK1 (0.40) EPHX1CA2CA12CA1CA9
SCHEMBL6009843 0.77 PDK1 (0.40) EPHX1CA2CA12CA1CA9
SCHEMBL6010036 0.77 PDK1 (0.40) EPHX1CA2CA12CA1CA9
SCHEMBL6008669 0.77 PDK1 (0.40) EPHX1CA2CA12CA1CA9
SCHEMBL5507249 0.75 ADH1B (0.39) HDAC6MLYCDEPHX1ADH1BADH1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183800-A1 Methods and fluorinated compositions for treating amyloid-related diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183800-A1 Methods and fluorinated compositions for treating amyloid-related diseases APP, PSEN1, TTR HDAC6 2174/4885MLYCD 2022/4885EPHX1 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.